SynthesisCurrent oncology reports2026
Deprescribing for Comorbidities in Patients with Cancer - a Systematic Review.
Synthesis in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPolypharmacy is highly prevalent among older adults with advanced cancer, particularly those with multimorbidity and limited life expectancy. The concurrent use of multiple medications increases the risk of potentially inappropriate medications (PIMs), drug–drug interactions, and adverse events, compromising quality of life and clinical outcomes. This systematic review aimed to examine current evidence on deprescribing for comorbidities in advanced cancer patients, identifying barriers and facilitators, frequent classes of PIMs, available tools to support deprescribing, and proposing a model to prioritise medications for discontinuation. RECENT
findingsReported barriers to deprescribing included prognostic uncertainty, fragmented care, time constraints, patient resistance, and clinician reluctance. Facilitators comprised interdisciplinary collaboration, pharmacist-led reviews, validated tools (e.g., STOPP/START, Beers Criteria, OncPal, OncoSTRIP), and patient-centred communication. Frequently identified PIMs included statins, antihypertensives, proton pump inhibitors, anticholinergic agents, and vitamins. Deprescribing was most effective when integrated into routine workflows and guided by systematic, goal-concordant approaches. Deprescribing in patients with advanced cancer and comorbidities is essential to mitigate the risks of polypharmacy. A structured, patient-centred process—supported by multidisciplinary teams and validated tools—is key to aligning pharmacological regimens with prognosis, functional status, and individual goals of care.
Indexed as
Identifiers
41945186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.